Abstract
The letter by Carver et al, to our knowledge, represents the fourth independent study documenting no change in response rates based on statin use in rituximab-treated patients with B-cell nonHodgkin’s lymphoma. In this regard, it provides an additional validation of previous studies indicating that concurrent statin use does not affect the clinical efficacy of rituximab and rituximabcontaining therapy. Although the apparent discordance between in vitro studies and the lack of clinical impact on patient outcome requires additional laboratory studies, it also illustrates that the potential for a loss in translation between the laboratory and clinic is a problem in making clinical decisions on the basis of in vitro studies alone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
